Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
76
AZN Quote, Financials, Valuation and Earnings
Last price:
$209.29
Seasonality move
:
6.02%
Day range:
$202.64 - $205.16
52-week range:
$122.48 - $212.71
Dividend yield:
1.56%
P/E ratio:
62.21x
P/S ratio:
10.83x
P/B ratio:
6.50x
Volume:
2.3M
Avg. volume:
3.8M
1-year change:
35.05%
Market cap:
$316.2B
Revenue:
$58.9B
EPS (TTM):
$3.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$15.4B | $1.08 | 8.1% | 35.97% | $135.50 |
|
BCYC
Bicycle Therapeutics Plc
|
$7.1M | -$0.95 | -21.41% | -6.65% | $18.80 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
GSK
GSK Plc
|
$6.1B | $0.62 | 9.41% | 17.04% | $57.10 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -75.07% | $2.65 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.75 | 14.07% | 25.94% | $869.96 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$203.98 | $135.50 | $316.2B | 62.21x | $2.15 | 1.56% | 10.83x |
|
BCYC
Bicycle Therapeutics Plc
|
$5.64 | $18.80 | $391.2M | -- | $0.00 | 0% | 13.79x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.13 | $17.94 | $947.8K | -- | $0.00 | 0% | 0.73x |
|
GSK
GSK Plc
|
$58.07 | $57.10 | $116.5B | 15.85x | $0.49 | 3.07% | 2.77x |
|
MREO
Mereo BioPharma Group Plc
|
$0.39 | $2.65 | $61.4M | -- | $0.00 | 0% | 120.46x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$770.79 | $869.96 | $81.5B | 18.55x | $0.94 | 0.47% | 5.84x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
37.84% | -0.049 | 10.39% | 0.52x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 1.520 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.310 | -- | 1.20x |
|
GSK
GSK Plc
|
51.97% | -0.225 | 24.36% | 0.51x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.707 | 0.12% | 8.09x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.69% | -0.011 | 3.64% | 3.29x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.2B | $2.9B | 13.53% | 23.12% | 18.93% | $1.1B |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
GSK
GSK Plc
|
$8B | $1.3B | 19.46% | 43.01% | 11.2% | $1.4B |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.2B | $898.6M | 13.66% | 14.93% | 23.13% | $880M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or BCYC?
Bicycle Therapeutics Plc has a net margin of 15.02% compared to AstraZeneca PLC's net margin of -503.67%. AstraZeneca PLC's return on equity of 23.12% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC72.19% $0.74 $78.3B BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About AZN or BCYC?
AstraZeneca PLC has a consensus price target of $135.50, signalling downside risk potential of -57.35%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $18.80 which suggests that it could grow by 233.33%. Given that Bicycle Therapeutics Plc has higher upside potential than AstraZeneca PLC, analysts believe Bicycle Therapeutics Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is AZN or BCYC More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.630, suggesting its more volatile than the S&P 500 by 63.002%.
-
Which is a Better Dividend Stock AZN or BCYC?
AstraZeneca PLC has a quarterly dividend of $2.15 per share corresponding to a yield of 1.56%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 15.28% of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or BCYC?
AstraZeneca PLC quarterly revenues are $15.5B, which are larger than Bicycle Therapeutics Plc quarterly revenues of $11.7M. AstraZeneca PLC's net income of $2.3B is higher than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.21x while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.83x versus 13.79x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.83x 62.21x $15.5B $2.3B BCYCBicycle Therapeutics Plc13.79x -- $11.7M -$58.7M
-
Which has Higher Returns AZN or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of 15.02% compared to AstraZeneca PLC's net margin of --. AstraZeneca PLC's return on equity of 23.12% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC72.19% $0.74 $78.3B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About AZN or BDRX?
AstraZeneca PLC has a consensus price target of $135.50, signalling downside risk potential of -57.35%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 15639.05%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than AstraZeneca PLC, analysts believe Biodexa Pharmaceuticals Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is AZN or BDRX More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.
-
Which is a Better Dividend Stock AZN or BDRX?
AstraZeneca PLC has a quarterly dividend of $2.15 per share corresponding to a yield of 1.56%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 15.28% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or BDRX?
AstraZeneca PLC quarterly revenues are $15.5B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. AstraZeneca PLC's net income of $2.3B is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.21x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.83x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.83x 62.21x $15.5B $2.3B BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns AZN or GSK?
GSK Plc has a net margin of 15.02% compared to AstraZeneca PLC's net margin of 8.44%. AstraZeneca PLC's return on equity of 23.12% beat GSK Plc's return on equity of 43.01%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC72.19% $0.74 $78.3B GSKGSK Plc69.38% $0.41 $45.3B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $135.50, signalling downside risk potential of -57.35%. On the other hand GSK Plc has an analysts' consensus of $57.10 which suggests that it could fall by -1.67%. Given that AstraZeneca PLC has more downside risk than GSK Plc, analysts believe GSK Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 GSKGSK Plc1 6 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.477, suggesting its less volatile than the S&P 500 by 52.337%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $2.15 per share corresponding to a yield of 1.56%. GSK Plc offers a yield of 3.07% to investors and pays a quarterly dividend of $0.49 per share. AstraZeneca PLC pays 15.28% of its earnings as a dividend. GSK Plc pays out 47.15% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $15.5B, which are larger than GSK Plc quarterly revenues of $11.5B. AstraZeneca PLC's net income of $2.3B is higher than GSK Plc's net income of $966.8M. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.21x while GSK Plc's PE ratio is 15.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.83x versus 2.77x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.83x 62.21x $15.5B $2.3B GSKGSK Plc2.77x 15.85x $11.5B $966.8M
-
Which has Higher Returns AZN or MREO?
Mereo BioPharma Group Plc has a net margin of 15.02% compared to AstraZeneca PLC's net margin of -2923.31%. AstraZeneca PLC's return on equity of 23.12% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC72.19% $0.74 $78.3B MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About AZN or MREO?
AstraZeneca PLC has a consensus price target of $135.50, signalling downside risk potential of -57.35%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $2.65 which suggests that it could grow by 586.36%. Given that Mereo BioPharma Group Plc has higher upside potential than AstraZeneca PLC, analysts believe Mereo BioPharma Group Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 MREOMereo BioPharma Group Plc4 1 0 -
Is AZN or MREO More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.310, suggesting its less volatile than the S&P 500 by 68.983%.
-
Which is a Better Dividend Stock AZN or MREO?
AstraZeneca PLC has a quarterly dividend of $2.15 per share corresponding to a yield of 1.56%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 15.28% of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MREO?
AstraZeneca PLC quarterly revenues are $15.5B, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. AstraZeneca PLC's net income of $2.3B is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.21x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.83x versus 120.46x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.83x 62.21x $15.5B $2.3B MREOMereo BioPharma Group Plc120.46x -- -- -$7M
-
Which has Higher Returns AZN or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 15.02% compared to AstraZeneca PLC's net margin of 21.74%. AstraZeneca PLC's return on equity of 23.12% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC72.19% $0.74 $78.3B REGNRegeneron Pharmaceuticals, Inc.81.22% $7.86 $34.2B -
What do Analysts Say About AZN or REGN?
AstraZeneca PLC has a consensus price target of $135.50, signalling downside risk potential of -57.35%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 12.87%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than AstraZeneca PLC, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC1 0 0 REGNRegeneron Pharmaceuticals, Inc.17 8 0 -
Is AZN or REGN More Risky?
AstraZeneca PLC has a beta of 0.336, which suggesting that the stock is 66.381% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.
-
Which is a Better Dividend Stock AZN or REGN?
AstraZeneca PLC has a quarterly dividend of $2.15 per share corresponding to a yield of 1.56%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.94 per share. AstraZeneca PLC pays 15.28% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or REGN?
AstraZeneca PLC quarterly revenues are $15.5B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. AstraZeneca PLC's net income of $2.3B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, AstraZeneca PLC's price-to-earnings ratio is 62.21x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 10.83x versus 5.84x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC10.83x 62.21x $15.5B $2.3B REGNRegeneron Pharmaceuticals, Inc.5.84x 18.55x $3.9B $844.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 14.29% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 10.81% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 6.6% over the past day.
